

Effects of Borax on Inflammation, Haematological Parameters and Total Oxidant-Antioxidant Status in Rats Applied 3-Methylcholanthrene ^[1]

Bahat COMBA ¹  Gökhan OTO ² Leyla MİS ¹ Hülya ÖZDEMİR ² Arzu COMBA ³

^[1] This study was presented at 3rd Anticancer Agent Development Congress, 18th-19th of May 2015, Izmir - Turkey

¹ Department of Physiology, Faculty of Veterinary Medicine, Yuzuncu Yil University, TR-65090 Van - TURKEY

² Department of Pharmacology, Faculty of Medicine, Yuzuncu Yil University, TR-65090, Van - TURKEY

³ Department of Urology, Dursun Odabas Medical Centre, Yuzuncu Yil University, TR-65090 Van - TURKEY

Article Code: KVFD-2016-15001 Received: 14.01.2016 Accepted: 26.03.2016 Published Online: 26.03.2016

Abstract

In this study was investigated effects of borax (BX) on inflammation markers, haematological parameters and total oxidant (TOS)-antioxidant status (TAS) in rats applied 3-methylcholanthrene (3-MC). In this research a total of 24 Wistar Albino rats were used. They were divided into 4 groups each containing 6 rats. 1st group was separated as a control group. 3-MC was applied twice a week first 2 weeks 25 mg/kg dose to the 2nd group with i.p. way. BX was given to 3rd group 300mg/L/day dose with drinking water during 150 days. 3-MC was applied twice a week first 2 weeks 25 mg/kg dose with i.p. way and BX were given with drinking water during 150 days to 4th group. At the end of the study blood analysis, tumor necrosis factor alpha (TNF- α) and interleukin 1 beta (IL-1 β) levels in 3-MC group; TOS and oxidative stress index (OSI), platelet (PLT) levels in 3-MC and 3-MC+BX groups showed significantly increases when compared to other groups. It was determined that lymphocytes % (LY%) of ever 3 groups were significantly higher; however, neutrophil % (NEU%) were significantly fewer according to control group. Haemoglobin (HGB) and hematocrit (HCT) values of 3-MC+BX groups showed significantly decrease according to other groups ($P \leq 0.05$). Mean corpuscular volume (MCV) in 3-MC and 3-MC+BX groups showed significantly decrease when compared to other groups ($P \leq 0.05$). As a result, in case of exposure to 3-MC, long-term use of BX with oral ways may not decrease oxidative stress, may changes haematological parameters such as, WBC, LY%, NEU%, PLT, HGB, HCT, MCV. However, these changes remain within physiological limits. Even so, in the use of BX should be considered use of iron. Furthermore, BX with the abovementioned dosage may be used to reduce the levels of TNF- α , IL-1 β , IL-6 being inflammation and cancer markers.

Keywords: Borax, Haematology, Inflammation, Interleukin, Rat, Tas, Tos, Tnf- α , 3-MC

3-Metilkolatren Uygulanan Sıçanlarda Boraksın İnflamasyon, Hematolojik Parametreler ve Total Oksidan-Antioksidan Durumlar Üzerine Etkileri

Özet

Bu çalışmada, 3-metilkolatren (3-MC) uygulanan sıçanlarda boraksın (BX) inflamasyon göstergeleri, hematolojik parametreler ve total oksidan (TOS)-antioksidan durumlar (TAS) üzerine etkileri araştırıldı. Çalışmada toplam 24 Wistar Albino sıçan kullanıldı. Sıçanlar her grupta 6'şar adet olacak şekilde 4 gruba ayrıldı. Birinci Grup kontrol grubu olarak ayrıldı. İkinci gruba 25 mg/kg dozunda haftada iki kez ilk 2 hafta 3-MC i.p. yolla uygulandı. Üçüncü gruba BX 300 mg/L/gün dozunda içme suları ile 150 gün boyunca verildi. Dördüncü gruba 3-MC 25 mg/kg dozunda haftada iki kez ilk 2 hafta i.p. yolla uygulandı ve BX 300 mg/L/gün dozunda içme suları ile 150 gün boyunca verildi. Çalışma sonunda kan analizlerinde, diğer gruplarla karşılaştırıldığında 3-MC grubunda tümör nekrozis faktör alfa (TNF- α) ve interlökin 1 beta (IL-1 β); 3-MC ve 3-MC+BX gruplarında ise, TOS, oksidatif stres indeksi (OSI) ve trombosit (PLT) seviyeleri istatistiksel önemde artış gösterdi. Kontrol grubuna göre her 3 gruptaki % lenfosit (%LY) seviyeleri yüksek; fakat % nötrofil (%NEU) seviyeleri önemli düzeyde düşük olduğu belirlendi. 3-MC+BX grubunda hemoglobin (HGB) ve hematokrit (HCT) değerleri diğer gruplara göre önemli bir azalma gösterdi ($P \leq 0.05$). 3-MC ve 3-MC+BX gruplarındaki ortalama alyuvar hacmi (MCV) diğer gruplarla karşılaştırıldığında önemli bir azalma gösterdi ($P \leq 0.05$). Sonuç olarak, 3-MC'ye maruziyet durumunda BX'in uzun süreli oral kullanımı oksidatif stresi azaltamayabilir, WBC, %LY, %NEU, PLT, HGB, HCT, MCV gibi hematolojik parametreleri değiştirebilir. Fakat bu değişimler fizyolojik sınırlar içerisinde kalır. Yinede BX'in kullanımında demir kullanımına dikkat edilmelidir. Ayrıca, bu dozda BX'in kullanımı inflamasyon ve kanser göstergeleri olan TNF- α , IL-1 β , IL-6 seviyelerini azaltabilir.

Anahtar sözcükler: Boraks, Hematoloji, İnflamasyon, İnterlökin, Sıçan, Tas, Tos, Tnf- α , 3-MC



İletişim (Correspondence)



+90 432 2251024/1546



bahatcomba@hotmail.com

INTRODUCTION

Boron (B) is an essential element being responsible in metabolic reactions, which affect physiological systems of organism. Borax (BX) mineral being a component of Boron on the other hand, is a boric acid salt ^[1]. Used especially in pharmaceutical industry, Borax is a necessary mineral as a trace element for human, animals and plants ^[2].

Borax affects activity ^[3], mineral metabolism (Ca and P) ^[4], hormones ^[5] and lipid metabolism ^[6], free radicals of many enzymes ^[7,8].

Being one of the unsaturated aromatic hydrocarbons, 3-methylcholanthrene (3-MC) is a chemical carcinogenic which is used in experimental studies. Therefore, it can be applied through hypodermic, peritoneal spread and oral ways to test animals ^[9].

Tumor necrosis alpha-factor (TNF- α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 β) are released by adipositis. Adipositis can initiate tumor formation in angiogenesis and cancer cells ^[10]. It is reported that these formations occur by means of cytokines such as TNF- α , IL-6, ve IL-1-receptor agonist ^[10,11].

Several pro-inflammatory cytokines released by innate and adaptive immune cells have been shown to regulate cancer cell growth and thereby contribute to tumor promotion and progression ^[12].

There is a remarkable balance between antioxidants and oxidants in a healthy body. Health problems occur due to a rise of free radicals or fall of antioxidants. Total antioxidant status (TAS) and total oxidant status (TOS) measurement is the most practical, economic and rapid practice that detects oxidant ^[13] and antioxidant ^[14] amounts.

There is limited information about whether any effects of BX on inflammation, TAS- TOS and haematological parameters in rats could be applied 3-MC. Therefore, in the present study, we have investigated the effect of BX on TNF- α , IL-1 β , IL-6, TAS, TOS, WBC, RBC, PLT values in rats applied 3-MC.

MATERIAL and METHODS

Study Groups

In this study were used total of 24 Wistar albino rats weighing between 200 and 250 g in a climate-controlled animal care facility, with a 12 h light/dark cycle. The animals were given with standard rat chow and water, *ad libitum*.

They were divided into 4 groups each containing 6 rats. Group 1 (Control) was separated as a control group and saline (1 mL of 0.9% NaCl) was injected twice a week first 2 weeks of study with i.p. way. Group 2 (3-MC) was applied 25 mg/kg dosage of 3-MC (Sigma- Aldrich Code: 213942)

2 twice a week first 2 weeks of study with i.p. way and was given normal drinking water during 150 days. Group 3 (BX) was given BX (Aldrich, Code: 2 21732) 300 mg/L/day dose with drinking water, during 150 days. Group 4 (3-MC+BX) was applied 25 mg/kg dosage of 3-MC twice a week first 2 weeks with i.p. way and BX was given 300mg/L/day dose with drinking water, during 150 days. All applications were simultaneously begun first day of study.

This study was approved by the local ethics committee of Yuzuncu Yil University (YUHADEK-Approval No: 2014/5).

Blood Collection

At the end of 150 days, blood samples were collected from all the rats and sacrificed by anesthetizing with a i.p. injection of 70 mg/kg of ketamine HCl (Ketalar, Pfizer) and xylazine HCl 10 mg/kg i. p. xylazine (Rompun, Bayer)

Blood samples were taken from hearts with sterile injector and placed into tubes with EDTA and coagulated tubes. Then bloods were separated into serum by centrifugation at 1.800 g (3.000 RPM) for 10 min. Serum was stored (-20°C) until the analysis.

Assay

The TNF- α , IL-1 β , IL-6 levels were analysis by ELISA kits (eBioscience, Austria); TAS, TOS values using a novel automated measurement method developed by Erel ^[13,14] by colorimetric kits (Rel Assay, Türkiye) in serum. The oxidative stress index (OSI) was calculated with the ratio of TOS to TAS.

Hematology parameters, WBC, % leukocyte, RBC, HGB, HCT, PLT, were determined using rat mode of veterinary the blood cell counter (Abocus Junior Vet-5, Austria) in whole blood.

Statistical Analysis

All data were analyzed using the Kruskal-Wallis test. Dunn test was performed to determine the different groups. Statistics Calculator taken as 5% level of significance and SPSS statistical software 16.0 for Windows was used for the calculations. The data was given as means \pm standard deviation (X \pm SD)

RESULTS

The serum levels of TNF- α , IL-1 β and IL-6 are shown in *Table 1*. According to the *Table 1* the levels of TNF- α (P \leq 0.05), IL-1 β (P \leq 0.05) and IL-6 in group 2 increased compared to other groups. But increase of IL-6 was not statistically significant.

The hematological parameters are shown in *Table 2*. According to the *Table 2* the increase of WBC levels in group 2 were not significantly compared to other groups. LY% levels of every 3 groups were significantly higher (P \leq 0.05);

however, its NEU% ($P \leq 0.01$) and MO% were lower than control group. But, MO% was not statistically significant. The HGB and HCT values of group 4, MCV in group 2 and group 4 were obtained significantly decrease ($P \leq 0.05$) compared to other groups. The PLT counts in groups 2 and 4 were determined significantly higher than others groups ($P \leq 0.05$) (Table 2).

The serum levels of TAS, TOS and OSI are shown in Table 3. According to the table 3 serum TOS and OSI levels in groups 2 and group 4 were determined significantly higher ($P \leq 0.01$) than other groups. There was no difference for TAS among the groups.

DISCUSSION

Being of great importance for environmental health, 3-MC changes metabolism and toxicity of physiological substances and drugs and leads to mutation after being taken into body. As a result of genotoxic effects of 3-MC, teratogenicity, leucemia, especially lung and cervix cancer types occur.

Cytokines are multi-functional polypeptides which are synthesized by various cells in body and have significant roles in the development of cellular, humoral immune and

Table 1. Serum TNF- α , IL-1 β and IL-6 levels in all the groups (mean \pm SD)

Tablo 1. Tüm gruplardaki serum TNF- α , IL-1 β and IL-6 seviyeleri

Inflammation Markers	Control Group n:6	3-MC Group n:6	BX Group n:6	3-MC+BX Group n:6	P Value
TNF- α (pg/mL)	309.76 \pm 24.83 ^b	379.70 \pm 44.37 ^a	312.92 \pm 34.11 ^b	305.31 \pm 67.45 ^b	≤ 0.05
IL-1 β (pg/mL)	301.72 \pm 95.76 ^b	481.85 \pm 79.06 ^a	365.94 \pm 80.08 ^b	339.70 \pm 89.88 ^b	≤ 0.05
IL-6 (pg/mL)	162.88 \pm 41.12	184.46 \pm 47.37	163.22 \pm 39.91	157.28 \pm 22.73	≥ 0.05

^{a,b} in the same line values with different letters show statistically significant differences

Table 2. The haematological parameters in all the groups (mean \pm SD)

Tablo 2. Tüm gruplardaki hematolojik parametreler

Haematological Parameters	Control Group n:6	3-MC Group n:6	BX Group n:6	3-MC+ BX Group n:6	P Value
WBC ($10^9/L$)	6.81 \pm 1.93	7.74 \pm 1.13	6.53 \pm 1.78	6.02 \pm 1.88	≥ 0.05
LY (%)	64.87 \pm 9.84 ^b	74.82 \pm 4.05 ^a	78.40 \pm 2.48 ^a	77.57 \pm 2.17 ^a	≤ 0.05
MO (%)	6.98 \pm 3.98	2.96 \pm 2.17	3.03 \pm 2.05	4.83 \pm 4.46	≥ 0.05
NEU (%)	28.13 \pm 6.29 ^a	22.18 \pm 2.79 ^b	18.57 \pm 2.69 ^b	17.58 \pm 3.88 ^b	≤ 0.01
RBC ($10^{12}/L$)	7.70 \pm 0.19	7.63 \pm 0.47	7.52 \pm 0.90	7.13 \pm 0.76	≥ 0.05
HGB (g/dL)	13.93 \pm 0.37 ^a	13.58 \pm 0.53 ^a	13.98 \pm 0.66 ^a	12.72 \pm 0.79 ^b	≤ 0.05
HCT (%)	45.74 \pm 1.34 ^a	43.80 \pm 2.45 ^a	44.43 \pm 5.55 ^a	40.71 \pm 4.18 ^b	≤ 0.05
MCV (fl)	59.50 \pm 1.52 ^a	57.60 \pm 1.49 ^b	59.17 \pm 2.23 ^a	57.33 \pm 1.37 ^b	≤ 0.05
MCH (pg)	18.10 \pm 0.30	17.88 \pm 0.49	18.88 \pm 3.47	17.95 \pm 1.66	≥ 0.05
MCHC (g/dL)	30.52 \pm 0.82	31.10 \pm 0.63	31.98 \pm 5.71	31.42 \pm 2.83	≥ 0.05
RDWc (%)	14.83 \pm 0.37	14.94 \pm 0.71	14.22 \pm 0.48	14.97 \pm 0.74	≥ 0.05
PLT ($10^9/L$)	607.00 \pm 69.57 ^c	715.83 \pm 71.37 ^b	605.50 \pm 75.63 ^c	779.17 \pm 67.81 ^a	≤ 0.05
PCT (%)	0.47 \pm 0.22	0.51 \pm 0.08	0.44 \pm 0.05	0.59 \pm 0.14	≥ 0.05
MPV (fl)	7.85 \pm 0.74	7.72 \pm 25.14	7.27 \pm 0.12	7.53 \pm 0.38	≥ 0.05
PDWc (%)	34.85 \pm 1.23	35.05 \pm 0.96	34.63 \pm 0.44	35.27 \pm 0.86	≥ 0.05

^{a,b,c} in the same line values with different letters show statistically significant differences

Table 3. Serum TAS-TOS and OSI values in all the groups (mean \pm SD)

Tablo 3. Tüm gruplardaki Serum TAS-TOS and OSI değerleri

Oxidant-Antioxidant Parameters	Control Group n:6	3-MC Group n:6	BX Group n:6	3-MC+BX Group n:6	P Value
TAS (mmol Trolox Equiv/L)	0.54 \pm 0.09	0.52 \pm 0.06	0.47 \pm 0.7	0.56 \pm 0.03	≥ 0.05
TOS (μ mol H ₂ O ₂ Equiv/L)	4.83 \pm 1.03 ^c	9.17 \pm 1.56 ^b	4.57 \pm 1.35 ^c	16.16 \pm 2.08 ^a	≤ 0.01
OSI (Arbitrary Unit)	0.89 \pm 0.13 ^c	1.76 \pm 0.36 ^b	0.96 \pm 0.28 ^c	2.89 \pm 0.42 ^a	≤ 0.01

^{a,b,c} in the same line values with different letters show statistically significant differences

inflammatory responses; supervising the cell growth and differentiation and initiating cicatrization processes [1,15]. Main cytokines being responsible for chronic inflammation are TNF- α , IL-6 and inflammasome-activated IL-1 β ; and TNF- α s and IL-6 play a significant role in cell growth and differentiation [16].

It has been emphasized that IL-6 being a significant cytokine that plays role in inflammatory response and pathogenesis of cancer [17] is a remarkable marker of experimental cancer, IL-6 levels rise in some cancer patients [18] and anti-apoptotic effects are observed in tumor cells [12].

In a study [9], serum IL-6 and TNF- α levels were investigated in fibrosarcoma induced by 3-MC (0.2 mg). The experiment took about 150-210 days until the appearance of tumor tissue in mouse. IL-6 and Tnf- α was higher than controls. In another study, 1 mg of 3-MC was injected into rats with i.p. way; it was determined that it leads to tumor with 66.6% rate and it was reported that 3-MC plays role in cancer biology by means of mutation directly or immune system depression indirectly [19]. In this study, levels of serum TNF- α and IL-1 β ($P \leq 0.05$), IL-6 in 3 MC group was higher than other groups; these values in BX+3MC group were similar to control group.

3-MC injected into rats with 30 mg/kg dosage leads to the synthesis of oncogenic proteins that can be used for the diagnosis [20,21]. In a study [22] detected that 3-MC injected with 200 mg/kg dosage leads to atrophy in thymus gland, T and B lymphopeny and cancer. However, in these study, ever 3 groups were demonstrated neutropenia ($P \leq 0.01$) and leucopeny ($P \leq 0.05$) according to control group. This finding could result from a chronic inflammation which was a result of 3-MC effect. As a matter of fact, it was reported that TNF- α has a toxic effect on β cells of pancreas, ensures vein adhesion of inflammatory cells, matures monocyte and macrophages and B and T lymphocytes [23,24]. In addition, IL-1 increases expression of surface molecules which help the aggregation of leucocytes; does not directly activate inflammatory leucocytes as neutrophil does, but affects mononuclear and endothelium cells instead; thus leads to the synthesis of chemokines that activate leucocytes [15,25].

IL-1 has also many inflammatory characteristics of TNF. For example, it was reported that IL-1 affects endothelium cells and increases coagulation [15,25]. In these study, the PLT counts in 3-MC and 3MC+BX groups were determined to be significantly higher ($P \leq 0.05$) while the MCV values significantly lower ($P \leq 0.05$) than other groups. At the same time, HGB and HCT values in 3MC+BX group were significantly decrease according to other groups ($P \leq 0.05$). However, these decreases were found to be within physiological limits. Furthermore, decrease of HGB and HCT and increase of PLT may be caused by iron deficiency. Although iron is an essential element for hemoglobin the free iron is moved binds to the transferrin, stored as proteins such as ferritin or hemosiderin complexes, it is

used holding in the hemoglobin and myoglobin. Because free iron is toxic for cells [26].

Oxidative stress is the imbalance between free radicals and antioxidant defense systems and associated with the etiology and progression of aging and many diseases [27-29]. Having genotoxic effects, 3-MC increases oxidative stress as well [30]. It is asserted that antioxidants taken through nutrition may decrease tumor incidents of antioxidants [20]. Anti-mutagens and antioxidants decrease oxidative stress and lead to decrease in genotoxicity and cancer risk [31].

Studies have demonstrated that B compounds are effective in maintaining the balance of prooxidants and antioxidants by reducing tissue damage resulting from oxidative stress [3,7,32]. Pawa and Ali [7] demonstrated that B limits oxidative damage by enhancing the glutathione store or inducing other free radical elimination.

In our study, TOS values were analyzed to assess the total effect of oxidants. Likewise, we measured the TAS level instead of evaluating antioxidant molecules separately.

In a study [32], B compounds supplementation in diet (100 mg/kg) significantly decreases the lipid peroxidation (LPO) and malondialdehyde (MDA) concentration, and enhances the antioxidant defense mechanism such as GSH in blood. However, in this study, serum TOS and OSI levels in 3MC and 3MC+BX (300 mg/L) groups were determined significant increase according to other groups ($P \leq 0.01$). This increase may be from iron deficiency in HGB and increase free iron in blood plasma. In this case free radicals and oxidative stress is increase [33]. Also this situation may be due to the difference in dose. Turkez et al. [8] reported that B did not alter MDA concentration at low doses (5-50 mg/L) but increased it at high doses (500 mg/L) in human peripheral blood. However, in this study this level of B is nontoxic. Because B compounds are given orally to animals for a short term, the LD50 values for borax in laboratory animals are in the range of approximately 400-700 mg B/kg of body weight [34,35]. Furthermore, the maximum tolerable level of B is 150 mg/kg; diet B deficiency may occur in animals when their diet contains B at 0.3 mg/kg [36].

Antioxidant capacity is an important factor in all physiological standards, and for the performance of humans and all animals [37,38]. Turkez et al. [8] observed that at low doses (15 mg/L) B compounds increased both SOD and CAT activities, while at high doses decreased (500 mg/L) in erythrocytes. Koç et al. [39], were demonstrated that B compounds (100 mg/kg), increases antioxidant capacity in spinal cord ischemia/reperfusion injury. However, in the present this study, serum TAS levels did not alter in between groups. This result is consistent with literature [32]. Ince et al. [32] showed that dietary B supplementation did not alter the plasma antioxidant capacity when compared to control. Turkez et al. [8] determined TAA in erythrocytes under *in vitro* conditions while we measured it in plasma,

which contains many nonspecific antioxidants such as urea, uric acid, and proteins^[32].

According to these studies, the use of BX different doses and time has been reported that its different effects are on oxidative stress and the antioxidant status, but it has not revealed their impact on inflammation markers and the haematological parameters. Therefore these effects of BX were evaluated in this study.

In summary in the present study, TNF- α and IL-1 β ($P \leq 0.05$), IL-6 ($P \geq 0.05$), WBC ($P \geq 0.05$) levels in 3-MC group, TOS and OSI ($P \leq 0.01$), PLT ($P \leq 0.05$) levels in 3-MC and 3-MC+BX groups were detected increases compared with other groups. It was determined that LY% levels of ever 3 groups were increased ($P \leq 0.05$); however, NEU% ($P \leq 0.01$) and MO% ($P \geq 0.05$) levels were decreased according to control group. Also, MCV in 3-MC and 3-MC+BX groups ($P \leq 0.05$), HGB and HCT values in 3-MC+BX group were decrease a physiology limited compared to other groups ($P \leq 0.05$).

As a result, this experimental study has demonstrated that 3MC may increase the level of inflammation and cancer markers, oxidative stress and some haematological parameters. In case of exposure to 3-MC, use alone of BX with 300 mg/L/day dosage with drinking water during 150 days does not decrease oxidative stress, may changes haematological parameters such as, WBC, LY%, NEU%, PLT, HGB, HCT, MCV. However, these changes remain within physiological limits. Even so, iron metabolism should be considered in the use of BX. Furthermore, BX with the abovementioned dosage may be used to reduce the levels of TNF- α , IL-1 β , IL-6 being inflammation and cancer markers.

REFERENCES

- Hunt CD, Idso JP:** Dietary boron as a physiological regulator of normal inflammatory response: A review and current research progress. *J Trace Elem Exp Med*, 12, 221-233, 1999. DOI: 10.1002/(SICI)1520-670X(1999)12:3<221::AID-JTRA6>3.0.CO;2-X
- Anaonymus:** Environmental Protection Agency. Toxicological review of boron and compounds. *IRIS Washington DC*. EPA/635/04/052. 2004.
- Hunt CD:** Regulation of enzymatic activity: One possible role of dietary boron in higher animals and humans. *Bio Trace Elem Res*, 66, 205-225, 1998. DOI: 10.1007/BF02783139
- Meacham SL, Taper LJ, Volpe SL:** Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes. *Environ Health Perspect*, 102, 79-82, 1994. DOI: 10.2307/3431967
- Kucukkurt I, Akbel E, Karabag F, Ince S:** The effects of dietary boron compounds in supplemented diet on hormonal activity and some biochemical parameters in rats. *Toxicol Ind Health*, 31, 255-60, 2015. DOI: 10.1177/0748233712469648
- Devirian TA, Volpe SL:** The physiological effects of dietary boron. *Crit Rev Food Sci Nutr*, 43, 219-231, 2003. DOI: 10.1080/10408690390826491
- Pawa S, Ali S:** Boron ameliorates fulminant hepatic failure by counteracting the changes associated with the oxidative stress. *Chem Biol Interact*, 160, 89-98, 2006. DOI: 10.1016/j.cbi.2005.12.002
- Turkez H, Geyikoglu F, Tatar A, Keles S, Ozkanc A:** Effects of some boron compounds on peripheral human blood. *Z Naturforsch*, 62, 889-896, 2007. DOI: 10.1515/znc-2007-11-1218
- Sacu D, Bildik A:** Levels of interleukin 6 and tumor necrosis factor- α in serum from fibrosarcoma induced rats. *Kafkas Univ Vet Fak Derg*, 15, 681-686, 2009. DOI: 10.9775/kvfd.2009.083-A
- Tilg H, Moschen AR:** Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol*, 6, 772-783, 2006. DOI: 10.1038/nri1937
- Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G:** Adiponectin expression from human adipose tissue relation to obesity, insulin resistance, and tumor necrosis factor expression. *Diabetes*, 52, 1779-1785, 2003. DOI: 10.2337/diabetes.52.7.1779
- Maximilian J, Waldner Foersch S, Neurath MF:** Interleukin-6—a key regulator of colorectal cancer development. *Int J Biol Sci*, 8, 1248-1253, 2012. DOI: 10.7150/ijbs.4614
- Erel O:** A new automated colorimetric method for measuring total oxidant status. *Clin Biochem*, 38, 1103-1111, 2005. DOI: 10.1016/j.clinbiochem.2005.08.008
- Erel O:** A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clin Biochem*, 37, 277-285, 2004. DOI: 10.1016/j.clinbiochem.2003.11.015
- Abbas AK, Lichtman AH, Poper JS:** Cytokines. Cellular and Molecular Immunology. 240-261, Philadelphia. WB Saunders Co. 1994.
- Hernandez H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA:** Obesity and inflammation: Epidemiology, risk factors, and markers of inflammation. *Int J Endocrinol*, 1-11, 2013. DOI: 10.1155/2013/678159
- Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D:** Interleukin-6 reduces lipoprotein lipase activity in adipose tissue of mice *in vivo* and in 3T3-L1 adipocytes: A possible role for interleukin-6 in cancer cachexia. *Cancer Res*, 52, 4113-4116, 1992.
- Oka M, Yamamoto K, Takahashi M, Hakozaaki M, Abe T, Lizuka N, Hazama S:** Relationship between serum levels of IL-6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. *Cancer Res*, 56, 2776-2780, 1996.
- Doğan A, Pınar A, Erdağ D, Bayazit M, Doğan E, Özcan K:** Effects of cysteamine on 3-methylcholanthrene - induced fibrosarcoma in mice. *Kafkas Univ Vet Fak Derg*, 19, 7-12, 2013. DOI: 10.9775/kvfd.2013.9329
- Polat F, Turaçlar N, Gül E, Özdemir Ö, Bingöl G:** Mutation analysis of the proto-oncogenes ki-rasand c-myc in the soft tissue tumors of the rats that were format by 3-methylcholanthrene *in vivo*. *J Sci Dumlupinar Univ*, 17, 11-18, 2008.
- Kuroda M, Oikawa K, Yoshida K, Takeuchi A, Takeuchi M, Usui M, Umezawa A, Mukai K:** Effects of 3-methylcholanthrene on the transcriptional activity and mRNA accumulation of the oncogene hWAPL. *Cancer Lett*, 221, 21-28, 2005. DOI: 10.1016/j.canlet.2004.08.006
- Lutz CT, Browne G, Petzold CR:** Methycholantrene causes increased thymocyte apoptosis. *Toxicology*, 128, 151-167, 1998. DOI: 10.1016/S0300-483X(98)00043-2
- Warne JP:** Tumour necrosis factor alpha: A key regulator of adipose tissue mass. *J Endocrinol*, 177, 351-355, 2003. DOI: 10.1677/joe.0.1770351
- Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG, Weetman AP, Ross RJ:** Leptin indirectly activates human neutrophils via induction of TNF-alpha. *J Immunol*, 172, 1809-1814, 2004. DOI: 10.4049/jimmunol.172.3.1809
- Oppenheim JJ, Ruscetti FW, Faltynek C:** Cytokines. In, Stites DP, Terr AI (Eds): Basic and Clinical Immunology.105-123, Appleton & Lange, East Nowalk, 1994.
- Zager RA:** Parenteral iron compounds: Potent oxidants but mainstays of anemia management in chronic renal disease. *Clin J Am Soc Nephrol*, 1 (Suppl. 1): 24-31, 2006. DOI: 10.2215/CJN.01410406
- Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW, McGuckin M, Traina T, Denduluri N, Turner S, Howard D, Jacobsen PB, Ahles T:** Thinking and living with cancer study.cognitive effects of cancer and its treatments at the intersection of aging: What do we know; what do we need to know? *Semin Oncol*, 40, 709-725, 2013. DOI: 10.1053/j.seminoncol.2013.09.006

- 28. Padurariu M, Ciobica A, Lefter R, Serban I L, Stefanescu C, Chirita R:** The oxidative stress hypothesis in Alzheimer's Disease. *Psychiatr Danub*, 25, 401-409, 2013.
- 29. Cojocaru IM, Cojocaru M, Sapira V, Ionescu A:** Evaluation of oxidative stress in patients with acute ischemic stroke. *Rom J Intern Med*, 51 (2): 97-106, 2013.
- 30. Lemaire B, Beck M, Jaspert M, Debier C, Calderon PB, Thome JB, Rees JF:** Precision-cut liver slices salmo salar as a tool to investigate the oxidative of CYP 1A-mediated PCP 126 and 3-methylcholanthrene metabolism. *Toxicol in Vitro*, 25, 335-342, 2011. DOI: 10.1016/j.tiv.2010.10.002
- 31. Hoffman GR, Shorter RA, Quaranta RL, McMaster PD:** Two mechanisms of antimutagenicity the aminothiols cysteamine and WR 1065 in *Saccharomyces cerevisiae*. *Toxicol in Vitro*, 13, 1-9, 1999. DOI: 10.1016/S0887-2333(98)00060-5
- 32. Ince S, Kucukkurt I, Cigerci IH, Fidan FA, Eryavuz A:** The effects of dietary boric acid and borax supplementation on lipid peroxidation, antioxidant activity, and DNA damage in rats. *J Trace Elem Med Biol*, 24, 161-164, 2010. DOI: 10.1016/j.jtemb.2010.01.003
- 33. Yılmaz K, Kahraman A, Bodur S, Koçar S, Köken T:** Reduced glutathione and antioxidant enzyme activities in erythrocytes of patients with iron-deficiency anemia. *Türkiye Klinikleri J Med Sci*, 24, 4, 305-8, 2004. DOI: 10.5799/ahinjs.01.2011.03.0056
- 34. Pfeiffer CC, Hallman LF, Gersh I:** Boric acid ointment: A study of possible intoxication in the treatment of burns. *J Am Med Assoc*, 128, 266-274, 1945, DOI:10.1001/jama.1945.02860210022006
- 35. Weir RJ, Fisher RS:** Toxicologic studies on borax and boric acid. *Toxicol Appl Pharmacol*, 23, 351-364, 1972, DOI:10.1016/0041-008X(72)90037-3
- 36. McDowell LR:** Boron. In, Cunha TJ (Ed): Minerals in Animal and Human Nutrition. 367-368, London, Academic Press, 1992.
- 37. Draper HH, McGirr LG, Hadley M:** The metabolism of malondialdehyde. *Lipids*, 21, 305-307, 1986. DOI: 10.1007/BF02536418
- 38. Bohloli M, Uzun H, Aytac E, Toklu AS, Paksoy M, Durak H, Ipek T:** Hyperbaric oxygen (HBO) therapy after partial hepatectomy: An experimental study on oxidative stress in rats. *Scand J Lab Anim Sci*, 34, 131-140, 2007.
- 39. Koc ER, Gökce EC, Sönmez MA, Namsulu M, Gökce A, Bodur AS.** Borax partially prevents neurologic disability and oxidative stress in experimental spinal cord ischemia/reperfusion injury. *J Stroke Cerebrovasc Dis*, 24, 83-90, 2015. DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.037